Dr Barry Drees returns to TriloDocs as an advisor
THE founder of an AI-platform which provides clinical reporting services has returned to the firm as an advisor following its acquisition by a global healthcare research leader.
TriloDocs was founded by US-born medical writer Dr Barry Drees.
With a PhD in Molecular Genetics from the University of California and postdoctoral research supported by the U.S. National Institutes of Health, Dr Drees is also a past President of the European Medical Writers Association (EMWA) and the former Editor in-Chief of the EMWA journal.
He is the brains behind TriloDocs, a tool that uses artificial intelligence to generate an initial draft of a clinical study report (CSR).
Dr Barry Drees (Pic: TriloDocs)
"Pulling from all source documents, the draft report accurately reflects the input material (protocol, statistical analysis plan, and the data tables and figures), leaving the crafting of the messages to the medical writer and the clinical team," a TriloDocs spokesperson explained.
"Building on years of knowledge from expert medical writers and combining this with the latest AI technology, we created a tool that is easy to use and incredibly powerful," they add.
"TriloDocs does what software does well – it quickly and consistently processes information and finds signals in data, leaving the humans to do the part they do best – interpreting the results."
The organisation was recently acquired by Genactis, a global leader in healthcare research and technology.
"This strategic move marks a significant milestone in TriloDocs' growth journey, positioning the company to scale innovation and deepen its commitment to transforming the way Medical Writing teams draft and deliver CSRs," TriloDocs said of the move.
"With Genactis' resources and global reach, TriloDocs is accelerating the product development roadmap, expanding support capabilities, and enhancing overall user experience, all while continuing to provide the same high-quality service and solutions our clients have come to expect," they added.
This week they confirmed that Dr Drees would return to work with the organisation as an advisor.
"We're proud to share that Dr Barry Drees, the founder of TriloDocs and the brilliant mind behind our rule-based AI - which applies expert medical writing knowledge to ensure unmatched data accuracy, has rejoined TriloDocs as an Advisor," the organisation said.
"Barry's return comes at a pivotal moment as we expand and refine our product offerings post-integration into the Genactis family," they added.
"His guidance will be instrumental in ensuring that TriloDocs remains the most accurate and reliable medical writing AI solution in the global market.
"We're thrilled to have him back and helping to shape what's next for TriloDocs."
For further information click here.
See More: Dr Barry Drees, Genactis, Trilodocs
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTÉ News
10 hours ago
- RTÉ News
Nike shares rally as turnaround takes shape amid tariff woes
Nike shares surged 10% in premarket trading today as an encouraging forecast and plans to reduce China production for US-bound goods bolstered confidence in an ongoing turnaround effort at the sportswear giant. Major US brands have spent years shifting away from Chinese factories as political tensions between Washington and Beijing escalated, but President Donald Trump's latest import tariffs are pushing companies to hasten their retreat. Nike plans to cut the percentage of US-bound goods made in China to a "high single-digit percentage range" by the end of May 2026. China currently accounts for about 16% of the shoes it imports into the United States. Trump's sweeping tariffs could also add around $1 billion to Nike's costs, executives said on Thursday, after the company posted its worst sales decline in roughly five years but gave a better-than-feared revenue forecast for the first quarter. "There was basically no profit, China was down 20%, that's not a good result... But as usual, the markets are pricing in what's coming and not what has been in the results," said Simon Jaeger, portfolio manager at Flossbach von Storch in Cologne, Germany, which holds shares in Nike. A lot of the focus was also on how Nike's running segment was bouncing back from a stretch of sluggish demand. The recovery was partly thanks to new CEO Elliott Hill's efforts to claw back market share in the running space with new launches. Nike has invested in running shoe and sneaker lines such as Pegasus and Vomero, and cut its stock of older models including the Air Force 1 and Air Jordan 1 through discounts. Hill is also looking to rekindle relationships with wholesale partners and expand its presence in more physical retailers as part of the wider revamp. "We think longer-term investors can now start to rotate back into the stock as one of the biggest potential turnarounds in consumer," analysts at Evercore ISI said in a note. Its results also helped shares of German peers Adidas and Puma and London-listed sportswear retailer JD Sports between 3% and 7%. "Nike executives also said they were nearly done with clearing out old inventory, which is a relief for Adidas, Puma, and JD Sports, who were having to compete with aggressive discounting from the bigger sportswear brand," Jaeger said. Nike shares are down 17.4% so far this year, while its 12-month forward price-to-earnings ratio is 1.90, compared with 1.58 and 0.64 for Adidas and Puma, respectively.
Irish Examiner
15 hours ago
- Irish Examiner
Tánaiste warns against EU-US trade deal delay, citing risk to jobs and investment
An extension of the deadline for an EU-US trade deal would not be positive, as it would prolong uncertainty for exporters, the Tánaiste has said. Simon Harris has urged negotiators to focus on reaching a deal before the July 9 deadline. On Thursday evening, White House press secretary Karoline Leavitt indicated that US president Donald Trump could extend the deadline for agreeing a deal with the EU, describing the cutoff as 'not critical.' Mr Harris said there must now be intensive engagement between the EU and US to prevent further uncertainty for businesses. 'We need to work really intensively to try and get a deal, at least a framework, a deal in advance of July 9, for one very big reason, uncertainty,' Mr Harris said. 'Uncertainty is causing people to pause their investment decisions. That has an impact on jobs. 'There's people in factories today in Ireland who want that certainty, businesses want certainty. So what we don't need is an elongation of the period of uncertainty.' Speaking in Cork, Mr Harris said many people working in the pharmaceutical sector may feel anxious about potential tariffs. However, he added that an agreement between the US and EU 'is possible.' 'In fact, I believe an agreement is absolutely essential, because the level of trade between the US and the EU is far too high to be sniffed at, regardless of who the occupant of the Oval Office is. 'We are interdependent, and certainly in my conversations with President Trump's Trade Representative, Ambassador Jamieson Greer, I specifically made the case that we need to come up with creative solutions in relation to the pharma industry that are good for the US and good for the EU, because our global supply chains are interdependent.' Mr Harris added that patients rely on pharmaceutical trade, saying 'creative solutions' are needed that work for both the EU and US. The US administration had previously threatened to impose a 50% tariff on EU goods, after President Donald Trump in May said talks were 'going nowhere.' That statement prompted a flurry of calls between senior EU and US diplomats, leading to the agreement of the July 9 deadline for talks. Earlier this week, Ireland's European Commissioner Michael McGrath said there might not be enough time for a 'comprehensive' trade deal between the EU and US, but he hoped the 'outline' of an agreement could be reached before then. Mr McGrath noted that experience shows comprehensive trade deals take significant time to complete. 'It may not be possible to have the level of detail that you would normally have in a trade agreement completed by July 9, but hopefully we can have the outline of the agreement that can provide the stability we need,' Mr McGrath said.
Irish Post
16 hours ago
- Irish Post
Dr Barry Drees returns to TriloDocs as an advisor
THE founder of an AI-platform which provides clinical reporting services has returned to the firm as an advisor following its acquisition by a global healthcare research leader. TriloDocs was founded by US-born medical writer Dr Barry Drees. With a PhD in Molecular Genetics from the University of California and postdoctoral research supported by the U.S. National Institutes of Health, Dr Drees is also a past President of the European Medical Writers Association (EMWA) and the former Editor in-Chief of the EMWA journal. He is the brains behind TriloDocs, a tool that uses artificial intelligence to generate an initial draft of a clinical study report (CSR). Dr Barry Drees (Pic: TriloDocs) "Pulling from all source documents, the draft report accurately reflects the input material (protocol, statistical analysis plan, and the data tables and figures), leaving the crafting of the messages to the medical writer and the clinical team," a TriloDocs spokesperson explained. "Building on years of knowledge from expert medical writers and combining this with the latest AI technology, we created a tool that is easy to use and incredibly powerful," they add. "TriloDocs does what software does well – it quickly and consistently processes information and finds signals in data, leaving the humans to do the part they do best – interpreting the results." The organisation was recently acquired by Genactis, a global leader in healthcare research and technology. "This strategic move marks a significant milestone in TriloDocs' growth journey, positioning the company to scale innovation and deepen its commitment to transforming the way Medical Writing teams draft and deliver CSRs," TriloDocs said of the move. "With Genactis' resources and global reach, TriloDocs is accelerating the product development roadmap, expanding support capabilities, and enhancing overall user experience, all while continuing to provide the same high-quality service and solutions our clients have come to expect," they added. This week they confirmed that Dr Drees would return to work with the organisation as an advisor. "We're proud to share that Dr Barry Drees, the founder of TriloDocs and the brilliant mind behind our rule-based AI - which applies expert medical writing knowledge to ensure unmatched data accuracy, has rejoined TriloDocs as an Advisor," the organisation said. "Barry's return comes at a pivotal moment as we expand and refine our product offerings post-integration into the Genactis family," they added. "His guidance will be instrumental in ensuring that TriloDocs remains the most accurate and reliable medical writing AI solution in the global market. "We're thrilled to have him back and helping to shape what's next for TriloDocs." For further information click here. See More: Dr Barry Drees, Genactis, Trilodocs
